Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Dec;35(12):2481–2485. doi: 10.1128/aac.35.12.2481

Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis.

M D Witt 1, A S Bayer 1
PMCID: PMC245416  PMID: 1810181

Abstract

Fluconazole and amphotericin B were compared in the prophylaxis and treatment of Candida albicans aortic endocarditis in a rabbit model. In the prophylaxis study, catheterized rabbits received, prior to intravenous (i.v.) challenge with C. albicans (2 x 10(7) blastospores), either no therapy, single-dose i.v. amphotericin B (1 mg/kg of body weight), single-dose fluconazole (50 mg/kg or 100 mg/kg i.v. or intraperitoneally [i.p.]), or fluconazole (50 mg/kg or 100 mg/kg i.v. or i.p.) with a second dose 24 h after inoculation. A single dose of amphotericin B was significantly more effective than either the one- or two-dose regimens of fluconazole at both 50 mg/kg (P less than 0.001 and P less than 0.03, respectively) and 100 mg/kg (P less than 0.01 and P less than 0.001, respectively) in the prevention of C. albicans endocarditis. In parallel treatment studies of established C. albicans endocarditis, i.v. amphotericin B (1 mg/kg) or i.p. fluconazole (50 mg/kg) was begun 24 or 60 h postinfection and continued daily for 9 or 12 days. At these dose regimens, amphotericin B was consistently more effective than fluconazole in reducing fungal vegetation densities, regardless of the timing of initiation of therapy. We also examined the efficacy of fluconazole at a daily dose of 100 mg/kg i.p. administered for 21 days in the treatment of established C. albicans endocarditis. When therapy was continued for 2 weeks or longer, fluconazole was more effective than no drug and approximately twice as effective as 12 days of amphotericin B in reducing intravegetation fungal densities. Our results suggest that amphotericin B is superior to fluconazole in both the prophylaxis and treatment of C. albicans endocarditis in the rabbit model. These findings may relate to the predominantly fungistatic activity of fluconazole against C. albicans in vitro.

Full text

PDF
2481

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crislip M. A., Edwards J. E., Jr Candidiasis. Infect Dis Clin North Am. 1989 Mar;3(1):103–133. [PubMed] [Google Scholar]
  2. Durack D. T., Beeson P. B. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol. 1972 Feb;53(1):44–49. [PMC free article] [PubMed] [Google Scholar]
  3. Durack D. T., Beeson P. B., Petersdorf R. G. Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br J Exp Pathol. 1973 Apr;54(2):142–151. [PMC free article] [PubMed] [Google Scholar]
  4. Filler S. G., Crislip M. A., Mayer C. L., Edwards J. E., Jr Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother. 1991 Feb;35(2):288–292. doi: 10.1128/aac.35.2.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  6. Horn R., Wong B., Kiehn T. E., Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985 Sep-Oct;7(5):646–655. doi: 10.1093/clinids/7.5.646. [DOI] [PubMed] [Google Scholar]
  7. Longman L. P., Hibbert S. A., Martin M. V. Efficacy of fluconazole in prophylaxis and treatment of experimental Candida endocarditis. Rev Infect Dis. 1990 Mar-Apr;12 (Suppl 3):S294–S298. doi: 10.1093/clinids/12.supplement_3.s294. [DOI] [PubMed] [Google Scholar]
  8. Norenberg R. G., Sethi G. K., Scott S. M., Takaro T. Opportunistic endocarditis following open-heart surgery. Ann Thorac Surg. 1975 May;19(5):592–604. doi: 10.1016/s0003-4975(10)64440-2. [DOI] [PubMed] [Google Scholar]
  9. Rotrosen D., Edwards J. E., Jr, Gibson T. R., Moore J. C., Cohen A. H., Green I. Adherence of Candida to cultured vascular endothelial cells: mechanisms of attachment and endothelial cell penetration. J Infect Dis. 1985 Dec;152(6):1264–1274. doi: 10.1093/infdis/152.6.1264. [DOI] [PubMed] [Google Scholar]
  10. Rubinstein E., Noriega E. R., Simberkoff M. S., Holzman R., Rahal J. J., Jr Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine (Baltimore) 1975 Jul;54(4):331–334. [PubMed] [Google Scholar]
  11. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Seelig M. S., Kozinin P. J., Goldberg P., Berger A. R. Fungal endocarditis: patients at risk and their treatment. Postgrad Med J. 1979 Sep;55(647):632–641. doi: 10.1136/pgmj.55.647.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Walsh T. J., Aoki S., Mechinaud F., Bacher J., Lee J., Rubin M., Pizzo P. A. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J Infect Dis. 1990 Apr;161(4):755–760. doi: 10.1093/infdis/161.4.755. [DOI] [PubMed] [Google Scholar]
  14. Walsh T. J., Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):460–475. doi: 10.1007/BF01962595. [DOI] [PubMed] [Google Scholar]
  15. Walsh T. J., Pizzo P. A. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol. 1988;42:517–545. doi: 10.1146/annurev.mi.42.100188.002505. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES